US Medicare Part D Inflation Is Real, MedPAC Rebate Data Show

The US Medicare Payment Advisory Commission shares its first looks at the impact of rebates in the Medicare Part D program. Rebates do indeed distort the overall spending trends, the analyses suggest – but underlying prices are still increasing relatively quickly.

drug costs
• Source: Alamy

The US Medicare Payment Advisory Commission’s first public presentation on analyses based on Part D rebate data show that drug price inflation in the program is, in fact, relatively high – even after accounting for rebates.

In a presentation during MedPAC’s 7-8 April meeting, MedPAC staff showed a comparison of the gross Part D drug spending...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Medicare

More from Government Payers